Physician profile

Peter R Scott

Cardiovascular Disease · Alcoa, TN

NPI 1326126269

$5,928.77

in general payments reported to CMS, 2019-2025

40 companies · $579 in 2025

The $579 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,952.38
Education$1.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $1,191.06 2019-2025 Lifevest
Pfizer INC. $723.50 2019-2025
Edwards Lifesciences Corporation $582.52 2019-2025 Sapien 3 Ultra Resilia
Amgen INC. $345.74 2019-2024 Repatha
E.R. Squibb & Sons, L.L.C. $293.38 2020-2025 Camzyos, Eliquis
Boston Scientific Corporation $275.46 2022-2025 Watchman Flx, Watchman, Watchman Access System
Merck Sharp & Dohme LLC $271.64 2021-2025 Verquvo
Janssen Pharmaceuticals, INC $224.50 2019-2023 Xarelto
Novartis Pharmaceuticals Corporation $195.90 2019-2024
Sanofi-Aventis U.S. LLC $186.59 2019-2024
Lantheus Medical Imaging, INC. $150.57 2019-2021
Abbott Laboratories $146.64 2022
Abiomed $129.64 2022-2024 Impella
Boehringer Ingelheim Pharmaceuticals, INC. $119.56 2019-2023 Jardiance
Kiniksa Pharmaceuticals International, Plc $112.05 2024 Arcalyst
Show all 40 companies
CompanyGeneral paymentsYearsTop products
Regeneron Healthcare Solutions, INC. $94.99 2019
Astrazeneca Pharmaceuticals LP $92.71 2020-2023 Farxiga
Bayer Healthcare Pharmaceuticals INC. $91.75 2022-2025
Actelion Pharmaceuticals US, INC. $81.44 2022-2024 Opsumit, Uptravi
Amarin Pharma, INC. $80.79 2019-2020
Baxter Healthcare $58.88 2023 Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor
Kiniksa Pharmaceuticals, LTD. $57.92 2023 Arcalyst
Esperion Therapeutics, INC. $48.11 2024 Nexletol
Philips North America LLC $40.21 2025 Ecc Solutions
Novo Nordisk INC $38.56 2024-2025 Wegovy
Alnylam Pharmaceuticals INC. $34.66 2022
Inspire Medical Systems, INC. $31.41 2024 Inspire
Gilead Sciences, INC. $27.50 2019
United Therapeutics Corporation $26.56 2025 Tyvaso
Cvrx, INC. $26.45 2023 Barostim Neo System
Daiichi Sankyo INC. $20.31 2024 Injectafer
Medtronic, INC. $19.44 2023 Linq II
Atricure, INC. $18.82 2024
Scpharmaceuticals INC. $18.77 2024
Biotronik INC. $16.23 2022
G Medical Diagnostic Services, INC. $13.20 2022
Cardiovascular Systems INC. $12.74 2021
Medtronic Vascular, INC. $12.36 2020
Irhythm Technologies, INC. $12.21 2022
Vivaquant INC, Dba Rhythm Express $4.00 2025 Rhythm Express

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter R Scott

$5,928.77

in general payments reported 2019-2025

Years
2019-2025
Top company
Zoll Services LLC (A/K/A Zoll Lifecor Corp)
Context
The $579 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/106119/peter-r-scott

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.